Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 233,367,664 papers from all fields of science
Search
Sign In
Create Free Account
Hemofil
Known as:
Hemofil HM
, Hemofil M
, Hemophil
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Factor VIII
factor VIII, human
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
On – Line Dialysate Filtration : A Method of Dialysate Endotoxin Removal or Only Reduction ?
M.
,
Fischbacha
,
+5 authors
Duringera
2008
Corpus ID: 3271386
Prof. M. Fischbach, Unité Nephrologie Dialyse, Transplantation, Pédiatrie 1, Hôpitaux Universitaires de Strasbourg Hautepierre, F…
Expand
2007
2007
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
G. Salvagno
,
J. Astermark
,
+5 authors
E. Berntorp
Haemophilia
2007
Corpus ID: 19595275
Summary. In order to describe the haemostatic role of a variation in inhibitor reactivity with different factor VIII (FVIII…
Expand
2005
2005
Monoclate-P — Hemofil-M study
S. Seremetis
Annals of Hematology
2005
Corpus ID: 19272703
In the United States, at least 70% of patients with severe hemophilia A who were treated prior to 1984 with concentrates are HIV…
Expand
1993
1993
Hemofili A Hastalarında Desmopressin'in Terapötik Etkinliği
Mustafa Yaylaci
,
Sabahattin Gül
,
Yasar Kucukardali
,
Gündüz Öztürk
,
M. Danaci
,
Necdet Üskent
1993
Corpus ID: 70677904
Hemofili A hastaları Faktör VIII konsantresi ya da kriyopresipitat kullandıkları takdirde hepatit, AİDS gibi viral enfeksiyon…
Expand
1989
1989
[Properties of factor VIII/von Willebrand factor in two highly-purified factor VIII concentrates, Hemofil M and Monoclate, using monoclonal antibodies].
I. Tanaka
,
A. Yoshioka
,
+7 authors
H. Fukui
[Rinsho ketsueki] The Japanese journal of…
1989
Corpus ID: 21174105
Properties of F. VIII/vWF in highly-purified factor VIII concentrates were examined using monoclonal antibodies. The F. VIII: C…
Expand
1987
1987
The incidence of HTLV-III/LAV seroconversion and non-A, non-B hepatitis in recipients of plasma products.
D. Piszkiewicz
,
H. Kingdon
,
M. L. Lee
,
J. Hooper
Developments in biological standardization
1987
Corpus ID: 10819102
Several groups including ours at Hyland have studied the incidence of HTLV-III/LAV seroconversion and non-A, non-B hepatitis…
Expand
1985
1985
The replacement therapy with quantitative infusion of fVIII concentrate and its merit on plasma level and total dose.
Nagasawa Hiroshi
,
Fukue Hidetaka
,
+4 authors
F. Katsuhiro
1985
Corpus ID: 75294945
On the basis of the in vitro stability of factor VIII concentrate at room temperature, continuous intravenous infusion of the…
Expand
1984
1984
Cryoprecipitate and factor VIII commercial concentrates:In vitro characteristics andin vivo compartmental analysis
M. Morfini
,
G. Longo
,
+6 authors
P. Rossi-Ferrini
La Ricerca in Clinica e in Laboratorio
1984
Corpus ID: 22256036
SummaryIn vitro andin vivo characteristics of cryoprecipitates and three commercial factor VIII concentrates (Kryobulin, Hemofil…
Expand
1972
1972
Factor VIII Concentrates in Outpatient Therapy
Charles M. Smith
,
G. Miller
,
R. Breckenridge
1972
Corpus ID: 71501538
Two factor VIII concentrates, Courtland and Hemofil, were evaluated during 64 courses of therapy in 26 classic hemophiliacs who…
Expand
1969
1969
Hemofil and other factor VIII concentrates.
The Medical letter on drugs and therapeutics
1969
Corpus ID: 1844768
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE